RBC Upgrade Sparks Buzz: Recent posts on X have highlighted a significant upgrade by RBC Capital, moving Colgate-Palmolive (CL) from Sector Perform to Outperform with a price target of $88. This news has stirred conversations among investors, with many focusing on the potential for a rebound after a tough year. The stock saw a modest rise following the announcement, fueling further interest.
Share Price Struggles: Discussion on X also centers on CL’s 14% share price decline this year, despite steady revenue and profit growth. Some users argue the stock is undervalued given its fundamentals, while others express caution due to broader market pressures. The disconnect between business performance and stock price remains a hot topic.
Future Outlook Debated: Sentiment on X includes curiosity about Colgate-Palmolive’s future, with mentions of innovations like agentic AI for productivity gains. Investors are split on whether recent institutional buying signals confidence or if selling by others hints at lingering doubts. The mix of optimism and skepticism keeps the conversation lively.
Note: This discussion summary was generated from an AI condensation of post data.
Colgate-Palmolive Insider Trading Activity
Colgate-Palmolive insiders have traded $CL stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CL stock by insiders over the last 6 months:
- SALLY MASSEY (Chief Human Resources Officer) sold 1,237 shares for an estimated $100,060
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Colgate-Palmolive Revenue
Colgate-Palmolive had revenues of $5.1B in Q3 2025. This is an increase of 1.95% from the same period in the prior year.
You can track CL financials on Quiver Quantitative's CL stock page.
Colgate-Palmolive Congressional Stock Trading
Members of Congress have traded $CL stock 9 times in the past 6 months. Of those trades, 2 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CL stock by members of Congress over the last 6 months:
- REPRESENTATIVE RICK LARSEN sold up to $15,000 on 10/06.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 09/25.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 4 times. They made 2 purchases worth up to $30,000 on 08/13, 06/17 and 2 sales worth up to $30,000 on 09/11, 06/24.
- REPRESENTATIVE TIM MOORE sold up to $15,000 on 09/10.
- SENATOR SHELLEY MOORE CAPITO sold up to $15,000 on 07/31.
- REPRESENTATIVE RITCHIE TORRES sold up to $15,000 on 07/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Colgate-Palmolive Hedge Fund Activity
We have seen 711 institutional investors add shares of Colgate-Palmolive stock to their portfolio, and 1,018 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 5,014,943 shares (+69.8%) to their portfolio in Q3 2025, for an estimated $400,894,543
- PRICE T ROWE ASSOCIATES INC /MD/ removed 4,206,156 shares (-11.5%) from their portfolio in Q3 2025, for an estimated $336,240,110
- WELLS FARGO & COMPANY/MN removed 3,901,175 shares (-50.9%) from their portfolio in Q3 2025, for an estimated $311,859,929
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 3,814,556 shares (+591.9%) to their portfolio in Q3 2025, for an estimated $304,935,606
- GQG PARTNERS LLC removed 2,861,718 shares (-20.1%) from their portfolio in Q3 2025, for an estimated $228,765,736
- PACER ADVISORS, INC. added 2,611,485 shares (+3052.2%) to their portfolio in Q3 2025, for an estimated $208,762,110
- DIAMOND HILL CAPITAL MANAGEMENT INC added 2,572,796 shares (+46.7%) to their portfolio in Q3 2025, for an estimated $205,669,312
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Colgate-Palmolive Analyst Ratings
Wall Street analysts have issued reports on $CL in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/09/2025
- Evercore ISI Group issued a "Outperform" rating on 11/03/2025
- Wells Fargo issued a "Underweight" rating on 11/03/2025
- Citigroup issued a "Buy" rating on 11/03/2025
- UBS issued a "Buy" rating on 11/03/2025
- Morgan Stanley issued a "Overweight" rating on 11/03/2025
- JP Morgan issued a "Overweight" rating on 10/10/2025
To track analyst ratings and price targets for Colgate-Palmolive, check out Quiver Quantitative's $CL forecast page.
Colgate-Palmolive Price Targets
Multiple analysts have issued price targets for $CL recently. We have seen 12 analysts offer price targets for $CL in the last 6 months, with a median target of $88.0.
Here are some recent targets:
- Nik Modi from RBC Capital set a target price of $88.0 on 12/09/2025
- Lauren Lieberman from Barclays set a target price of $80.0 on 11/04/2025
- Peter Grom from UBS set a target price of $90.0 on 11/03/2025
- Andrea Teixeira from JP Morgan set a target price of $87.0 on 11/03/2025
- Robert Ottenstein from Evercore ISI Group set a target price of $94.0 on 11/03/2025
- Chris Carey from Wells Fargo set a target price of $77.0 on 11/03/2025
- Filippo Falorni from Citigroup set a target price of $95.0 on 11/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
